Adnkronos "We are here to fight respiratory syncytial virus (RSV) with an extraordinary response based on scientific discoveries, providing parents and newborns with the opportunity to protect themselves from this terrible infection. This new technology offers safe and universal protection as it is not linked to the child's weight." These are the words of Nicoletta Luppi, President and CEO of MSD Italia, speaking at the press conference held in Rome by the pharmaceutical company on the occasion of the approval of the monoclonal antibody clesrovimab by the Italian Medicines Agency (AIFA).
https://www.youtube.com/watch?v=QK5RsvzYrp8
Continue on the app
The news of your city, in real time.
Open in app